Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPSC NK Cell Therapy in Relapsed/Refractory AML or AML MRD
NCT05987696Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2023
- Primary completion
- Jan 2025
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLL1 CAR-NK cell, QN-023a and super NK cell in acute myeloid leukemia (AML) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days and Incidence of Dose Limiting Toxicities at 28 days. Started Jul 2023; status: completed.
02
Drugs
CLL1 CAR-NK cellQN-023asuper NK cell
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05987696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987696.